- 12-patient cohort fully enrolled with an average time since transplant of approximately 8 months - 100% insulin independence achieved in 10 patients who are over 4 weeks post-transplant - No signs of graft rejection or de novo donor-specific HLA antibodies - Tegoprubart continues to demonstrate a favorable safety and tolerability profile IRVINE, Calif, March 16, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced updated results from an investigator-initiated tr ...